Genspera Inc  

(Public, OTCMKTS:GNSZ)   Watch this stock  
Find more results for Genspera, Inc.�
0.000 (0.00%)
Delayed:   2:22PM EST
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.54 - 1.42
Open     -
Vol / Avg. 0.00/42,107.00
Mkt cap 31.12M
P/E     -
Div/yield     -
EPS -0.26
Shares 32.76M
Beta 0.22
Inst. own 0%
Feb 9, 2015
Genspera Inc at Biotechnology Industry Organization CEO & Investor Conference
Jan 19, 2015
Genspera Inc at Noble Financial Equity Conference

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -160.76% -164.20%
Return on average equity -346.42% -1993.23%
Employees 2 -
CDP Score - -


2511 N. Loop 1604 W. Suite 204
San Antonio, TX 78258
United States - Map
+1-210-4798112 (Phone)
+1-800-2535177 (Fax)

Website links


GenSpera Inc. (GenSpera) is a development-stage pharmaceutical company. The Company is focused on the development of prodrug cancer therapeutics for the treatment of solid tumors including prostate, liver, brain and other cancers. A prodrug is an inactive precursor of a drug that is converted into its active form only at the site of the tumor. The Company has four prodrug candidates: G-202, G-114, G-115 and G-301. The Company�s primary focus is the clinical development of its compound, G-202, a therapeutic agent with a mechanism of action. G-202 is in Phase II Clinical Trial. G-114 is validated efficacy in pre-clinical animal models. Pilot toxicology is completed for G-115. G-301 is validated efficacy in pre-clinical animal models. The Company is also conducting a Phase II clinical trial to test the utility of G-202 in patients with hepatocellular carcinoma (liver cancer). As of March 27, 2013, it treated one patient in this Phase II trial.

Officers and directors

Craig A. Dionne Ph.D. Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer
Age: 55
Russell Richerson Ph.D. Chief Operating Officer, Secretary
Age: 61
Peter E. Grebow Ph.D. Independent Director
Age: 67
Bo Jesper Hansen M.D., Ph.D. Independent Director
Age: 57
Scott V. Ogilvie Independent Director
Age: 58